Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.49 |
| ▸ | HTR2C | P28335 | 7/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.47 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405593 | 0.93 | HTR2A (0.49) | HTR2AHTR2CDRD2CHRM3OPRM1 | |
| SCHEMBL3410692 | 0.79 | OPRL1 (0.65) | HTR2ADRD2OPRM1OPRL1 | |
| SCHEMBL3405578 | 0.77 | OPRM1 (0.38) | OPRM1OPRL1 | |
| SCHEMBL3403549 | 0.75 | OPRL1 (0.49) | OPRM1OPRL1 | |
| SCHEMBL11768433 | 0.71 | HTR2A (0.69) | HTR2AHTR2CDRD2OPRL1 | |
| SCHEMBL3407006 | 0.71 | SIGMAR1 (0.41) | OPRM1OPRL1 | |
| Ammonia Solution, Strong SCHEMBL27835975 | 0.71 | HTR2A (0.44) | HTR2AHTR2CDRD2CHRM3 | |
| SCHEMBL3434090 | 0.70 | SIGMAR1 (0.41) | OPRM1OPRL1 | |
| SCHEMBL4099911 | 0.70 | OPRL1 (0.51) | DRD2OPRM1OPRL1OGFRL1 | |
| SCHEMBL3409398 | 0.70 | OPRL1 (0.51) | HTR2AHTR2CDRD2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206156-B2 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | claimed |
| EP-2254883-B1 | SUBSTITUTED INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-11-26 | — | — | EP | claimed |
| CN-102015683-A | Substituted indole derivatives | GRUENENTHAL GMBH | 2011-04-13 | — | — | CN | claimed |
| EP-2254883-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-01 | — | — | EP | claimed |
| WO-2009103552-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-08-27 | — | — | WO | claimed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| US-9206156-B2 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206156-B2 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| EP-2254883-B1 | SUBSTITUTED INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2254883-B1 | SUBSTITUTED INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20130116283-A1 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2013-05-09 | — | — | US | disclosed |
| US-20130116283-A1 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2013-05-09 | — | — | US | disclosed |
| CN-102015683-A | Substituted indole derivatives | GRUENENTHAL GMBH | 2011-04-13 | — | — | CN | disclosed |
| WO-2009103552-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-08-27 | — | — | WO | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215828-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | HTR2A 12/4885HTR2C 16/4885DRD2 311/4885 |
| US-20130116283-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | HTR2A 12/4885HTR2C 16/4885DRD2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.